从遗传角度看“不明原因肝病”的临床基因诊断*

doi:10.3969/j.issn.1672-5069.2018.01.002

Abstract

Li Xinhua, Chong Yutian. Genetic diagnosis of liver diseases with unknown causes:From the point of heredity[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(1): 4-9.

[1] Sanyal AJ,Boyer TD,Terrault N,et al. Zakim and Boyer’s hepatology:a textbook of liver disease. 7th ed:Philadelphia,PA:Elsevier,2018.
[2] Houten SM,Violante S,Ventura FV,et al. The biochemistry and physiology of mitochondrial fatty acid beta-oxidation and its genetic disorders. Annu Rev Physiol,2016,78:23-44.
[3] Lok CY,Merryweather-Clarke AT,Viprakasit V,et al. Iron overload in the Asian community. Blood,2009,114:20-25.
[4] Bandmann O,Weiss KH,Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol,2015,14:103-113.
[5] Parenti G,Andria G,Ballabio A. Lysosomal storage diseases:from pathophysiology to therapy. Annu Rev Med,2015,66:471-486.
[6] Pant M,Oshima K. Cholesteryl Ester Storage Disease:An underdiagnosed cause of cirrhosis in adults. Ann Diagn Pathol,2017,[ahead of print].
[7] Miyajima H. Aceruloplasminemia. In:Adam MP,Ardinger HH,Pagon RA,Wallace SE,Bean LJH, Mefford HC,et al. eds. Gene Rev. Seattle （WA）,1993.
[8] Zhang MH,Knisely AS,Wang NL,et al. Fibrinogen storage disease in a Chinese boy with de novo fibrinogen Aguadilla mutation:Incomplete response to carbamazepine and ursodeoxycholic acid. BMC Gastroenterol,2016,16:92.
[9] Da Costa L,Galimand J,Fenneteau O,et al. Hereditary spherocytosis,elliptocytosis,and other red cell membrane disorders. Blood Rev,2013,27:167-178.
[10] Farashi S,Harteveld CL. Molecular basis of alpha-thalassemia. Blood Cells Mol Dis,2017,[ahead of print].
[11] Memon N,Weinberger BI,Hegyi T,et al. Inherited disorders of bilirubin clearance. Pediatr Res,2016,79:378-386.
[12] EASL Clinical Practice Guidelines:management of cholestatic liver diseases. J Hepatol,2009,51:237-267.、
[13] Joshi D,Gupta N,Samyn M,et al. The management of childhood liver diseases in adulthood. J Hepatol,2017,66:631-644.
[14] Kotalova R,Dusatkova P,Cinek O,et al. Hepatic phenotypes of HNF1B gene mutations:a case of neonatal cholestasis requiring portoenterostomy and literature review. World J Gastroenterol,2015,21:2550-2557.
[15] Viveiros A,Reiterer M,Schaefer B,et al. CCBE1 mutation causing sclerosing cholangitis:Expanding the spectrum of lymphedema-cholestasis syndrome. Hepatology,2017,66:286-288.
[16] Guay-Woodford LM,Bissler JJ,Braun MC,et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease:report of an international conference. J Pediatr,2014,165:611-617.
[17] Vilarinho S,Sari S,Yilmaz G,et al. Recurrent recessive mutation in DGUOK causes idiopathic non-cirrhotic portal hypertension. Hepatology,2016,34:127-132.
[18] Jackson SB,Villano NP,Benhammou JN,et al. Gastrointestinal manifestations of hereditary hemorrhagic telangiectasia（HHT）:A systematic review of the literature. Dig Dis Sci,2017,62:2623-2630.
[19] Varga EA,Kujovich JL. Management of inherited thrombophilia: guide for genetics professionals. Clin Genet,2012,81:7-17.
[20] Walker V. Ammonia metabolism and hyperammonemic disorders. Adv Clin Chem,2014,67:73-150.
[21] Xiong X,Chen M,Lim WA,et al. CRISPR/Cas9 for human genome engineering and disease research. Annu Rev Genomics Hum Genet,2016,17:131-154.
[22] Ruiz de Galarreta M,Lujambio A. Therapeutic editing of hepatocyte genome in vivo. J Hepatol,2017,67:818-828.
[23] Li Q,Wang K. InterVar:Clinical interpretation of genetic variants by the 2015 ACMG-AMP guidelines. Am J Human Genet,2017,100:267-280.
[24] Li XH,Lu Y,Ling Y,et al. Clinical and molecular characterization of Wilson's disease in China: identification of 14 novel mutations. BMC Med Genet,2011,12:6.
[25] Innocenti F,Grimsley C,Das S,et al. Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics,2002,12:725-733.
[26] Song YZ,Zhang ZH,Lin WX,et al. SLC25A13 gene analysis in citrin deficiency:sixteen novel mutations in East Asian patients,and the mutation distribution in a large pediatric cohort in China. PLoS One,2013,8:e74544.
[27] Dixon PH,van Mil SW,Chambers J,et al. Contribution of variant alleles of ABCB11 to susceptibility to intrahepatic cholestasis of pregnancy. Gut,2009,58:537-544.

Genetic diagnosis of liver diseases with unknown causes:From the point of heredity

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lu Lungen. Cholestatic liver diseases：What we know and how to deal with [J]. Journal of Practical Hepatology, 2019, 22(5): 754-757.
[2]	Hong Jia, Wu Xiaoning, You Hong. Standardized diagnosis of cholestatic liver diseases [J]. Journal of Practical Hepatology, 2019, 22(5): 758-760.
[3]	Wang Haifang, Yang Dawei, Jia Bei. Impact of nutrition support and medusa administration on liver function, erythrocyte and platelet parameters in patients with alcoholic liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 381-384.
[4]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[5]	Zhong Yan, Su Shuting, Mi Yuqiang.. Treatment of patients with nonalcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 145-148.
[6]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[7]	Huang Faguang, Li Xiaocheng, Gong Jianping, et al.. Research on insulin resistance related protein molecules in human liver tissues by comprehensive gene expression profiling analysis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 872-876.
[8]	Guo Baona, Zhan Yutao.. Clinical features of alcoholic liver diseases:An analysis of 79 cases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 877-880.
[9]	Pu Yonglan, Chen Yuanwen, Fan Jiangao.. Gluten intestinal disease and nonalcoholic fatty liver: One case report [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 981-982.
[10]	Gao Miaomiao, Zhang Jiyuan, Zou Zhengsheng.. Myeloid-derived suppressor cells in the pathogenesis of liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 813-816.
[11]	Wang Dengbin. Progress of imaging technologies for diagnosis of liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 489-492.
[12]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[13]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[14]	Zeng Minde. Mechanisms of lipotoxicity in pathogenesis of nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 153-156.
[15]	Zhang Zhihua, Gu Tianyi, Chen Liuying, et al. Meta analysis of efficacy of ornithine aspartate in the treatment of patients with fatty liver [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(2): 233-236.